Q4 2024 showed a significant miss in profitability despite a 4% YoY sales growth; gross profit margin dropped due to a one-time discount for a new big client. The FDA initiatives are interesting, but
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sard
Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.26 per share a year ago.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for
Sensus Healthcare (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in
Sensus Healthcare, Inc. (SRTS) closed at $6.92 in the latest trading session, marking a +1.91% move from the prior day.
Sensus Healthcare, Inc. (SRTS) reachead $6.77 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close.
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.83, representing a -1.87% change from its previous close.
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $7.21, representing a -1.77% change from its previous close.
Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $7.10, marking a -1.53% move from the previous day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Sensus Healthcare (SRTS). While the effectiveness of this highly sought-after metric is questionable, th
Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE